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BACKGROUND: A bicuspid aortic valve (BAV) is a common congenital heart disease, which affects 1-2% of the population. 
However, the relationship between BAVs and aortic dilation has not been sufficiently elucidated.
METHODS: A total of 241 BAV patients who were referred to this  hospital for cardiac surgey over a 4.75-year period were in-
cluded in this study. In addition to the clinical characteristics of the included patients, the morphological features of the aortic valve 
and aorta, the length of the left main coronary artery, and the laboratory findings (the coagulation and hematological parameters as 
well as the total cholesterol concentration) were determined and compared with those of the tricuspid aortic valve (TAV) patients.
RESULTS: The BAV patients were younger than the TAV patients for a valve surgery in the last 3 months of the study period. The 
BAV patients were predominantly male. Most of the BAVs that were surgically treated were stenotic, regurgitant, or combined, and 
only 19 (7.88%) were normally functioning valves. According to echocardiography or operative records, 148 (78.31%) were type 
A, 31 (16.40%) were type B, and 10 (5.29%) were type C. The left main coronary artery was much shorter in the BAV patients than 
it was in the TAV patients. There was no significant difference between BAV and TAV patients in the total cholesterol concentra-
tions; whereas differences were noted between patients receiving lipid-lowering therapy and those not receiving lipid-lowering 
therapy. The dimensions of the aortic root, sinotubular junction, and ascending aorta were beyond normal limits, while they were 
significantly smaller in the BAV patients than in the TAV patients. They were also much smaller in patients receiving statin therapy 
than those not receiving statin therapy in both groups. Moreover, the aortic dilation in the BAV group was found to be significantly 
associated with patient age.
CONCLUSIONS: The BAV patients developed aortic wall and aortic valve disorders at a younger age than the TAV patients and 
were predominantly male. Aortic dilation was observed in the aortic root, sinotubular junction, and ascending aortic segments in 
both the BAV and TAV patients undergoing surgical aortic valve replacement, although the BAV patients had a smaller degree of 
dilation than the TAV patients, and dilation was also significantly age-related in this group. The shorter left main coronary artery that 
the BAV patients possess may contribute to the progressive course of aortic dilation that these patients experience. Statin therapy 
did not affect the aortic annulus in either group, but did decrease the dimensions of the aortic root, sinotubular junction and ascend-
ing aorta. In general, statin therapy had a better effect on the aortas of the TAV patients than it did on those of the BAV patients.
KEYWORDS: Aortic dilation; Aortic valve disorder; Bicuspid aortic valve; Cholesterol; Left main coronary artery.
INTRODUCTION
A bicuspid aortic valve (BAV) is a common congenital 
heart disease. It is observed in 1-2% of the entire population1 
and in 31.9% of individuals with aortic valve disorders.2 A 
BAV may be accompanied by aortic stenosis or insufficiency, 
infective endocarditis, an aortic aneurysm or an aortic 
dissection. It can also be associated with aortic coarctation 
and Marfan’s syndrome.1 Aortic dilation begins at an early 
age in the BAV patients and is usually characterized by 
“mid-ascending”-type dilation.3 The dilation process can 
be observed even in patients with normally functioning 
BAVs.4-7 The increased stress on the aortic wall that results 
from the recirculation vortices produced by the abnormal 
opening of the BAVs has been recognized as a risk factor 
for aortic dilation.3 The intrinsic links between the BAVs 
and aortic dilation have given rise to a concept that the 
498
CLINICS 2010;65(5):497-505The Bicuspid Aortic Valve
Yuan SM et al.
Copyright © 2010 CLINICS
BAVs represent a disorder that affects both the aortic valve 
and the aorta3,6,7 and have led some authors to suggest 
early replacement of the aorta instead of isolated valve 
replacement in such patients.8,9 In spite of multiple previous 
morphological investigations, 2,10 little is known concerning 
the relationship between the BAVs and aortic dilation.7 The 
goal of this study is to describe the relation between the BAV 
and aortic dilation in addition to its clinical implications and 
morphological characteristics by comparing to those of the 
TAV.
PATIENTS AND METHODS
Patient selection. We performed a retrospective search 
for the BAV patients who were referred to this hospital for 
cardiac surgery between January 1, 2004 and September 
30, 2008 using the Doctor’s Record Database by examining 
perfusionists’ records. Patients who came in for a repeated 
operation whose native aortic valve (bicuspid, tricuspid, or 
unknown) had been replaced in their primary operations 
within or outside of the study period were excluded from 
the present study. As a result, a total of 241 patients were 
included in the BAV group.
Controls. Patients with a tricuspid aortic valve (TAV) 
referred to this hospital for a cardiac operation for an 
isolated aortic dilation, a combined aortic dilation and 
aortic valve abnormality, coarctation of the aorta, Marfan’s 
syndrome, or aortic dissection during the entire study period 
as well as those with infective endocarditis or aortic valve 
disorders who were seen during the last three months of the 
study period were included in the study as control patients. 
As a result, a total of 225 patients were included in the 
control group.
Observations. The patients’ surgical indications, the 
characteristics of their BAVs, and the location of their aortic 
dilations were recorded. The pathological types of the BAVs 
were determined based on a short axis view of the pre- or 
intraoperative echocardiograms, which were either viewed 
on the Horizon Cardiology Web of this hospital or taken 
from the operative records. The dimensions of the aorta were 
measured at four levels on the long axis view of the archived 
echocardiogram: the aortic annulus, the aortic sinus, the 
sinotubular junction and the ascending aorta. The length 
of the left main coronary artery was measured on the right 
anterior oblique view of the archived coronary angiography 
images. Perioperative laboratory findings (the coagulation 
and hematological parameters as well as the total cholesterol 
concentration) were collected from the “Autolab” database 
of the hospital and analyzed. The laboratory values of the 
BAV group were compared to those of the control group.
Statistical analysis. Data were expressed as means±SDs. 
Unpaired t-tests were used in comparative analyses. Two-
tailed p-values <0.05 were considered to be statistically 
significant.
RESULTS
A total of 241 consecutive patients with a BAV were 
referred to this hospital for a cardiac operation during the 
study period, representing 6.71% of 3,594 adult patients 
during the same period. The group included 186 males 
and 55 females. The mean age of the BAV patients was 
56.129 ± 15.096 (range, 16-85) years, which was much 
lower than that of the TAV patients (Table 1). Their surgical 
indications included diseases of the aorta (aortic dilation, 
combined aortic dilation and aortic valve disorder, aortic 
dissection, coarctation of the aorta, and Marfan’s syndrome) 
and valvular disorders (aortic valve disorder, infective 
endocarditis, and mitral valve regurgitation) (Table 2). 
The cardiopulmonary bypass time was 109.39±35.92 
(range, 46-324) min (n=236), the aortic cross-clamp time 
was 83.74±28.15 (range, 29-225) min (n=236), the total 
circulatory arrest time was 16.292±5.385 (range, 8-35) min 
(n=24), and the minimal core temperature of the patients 
during total circulatory arrest was 18.138±2.225 (range, 15-
20) °C (n=13). The postoperative morbidity rate was 4.98%. 
The postoperative complications included atrial fibrillation 
(n=2), cerebrovascular accident (n=2), prosthetic aortic 
valve leak (n=4), prosthetic valvular endocarditis (n=2), and 
spontaneous cerebral hemorrhage (n=1). One patient with 
poor left ventricular function who underwent aortic valve 
replacement and repeated coronary artery bypass died 27 
days after the operation, yielding a mortality rate of 0.41%. 
The BAV was stenotic in 122 patients, regurgitant in 62 
patients, combined stenotic and regurgitant in 3 patients, and 
normal in 19 patients, respectively (Table 3). 
Data regarding the type of the BAV that a patient had 
were not available for 52 patients. In the remaining patients, 
the BAV type was determined from the short axis view of the 
preoperative transthoracic or intraoperative transesophageal 
echocardiograms in 186 patients and from the operative 
record in the other 3 patients. A total of 148 (78.31%) 
patients had type A BAVs, 31 (16.40%) had type B BAVs, 
and 10 (5.29%) had type C BAVs (Figure 1). In the short 
axis view of the echocardiogram of one patient with a type 
A BAV, the aortic valve appeared to have three commissures 
during diastole, but leaflet doming was visible during systole 
(Figure 2). The aortic valve of that patient proved to be 
bicuspid at the time of surgery. The configuration of the 
BAV cusps was unknown in 49 cases. Of the remaining 192 
patients, 132 (68.75%) patients had calcified valves and 60 
(31.25%) patients had valves that exhibited doming.
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Table 1 - Clinical characteristics of included patients.
Variable BAV TAV p-value
Case, n 241 225
Gender, n (M:F) 186/55 (3.38:1) 144/81 (1.78:1) 
Age (year) 56.129±15.096 (16-85, n=241) 62.842±14.724 (17.5-88, n=225) <0.0001 
Left ventricular ejection fraction (%) 57.44±8.28 (15-78) 57.14±8.08 (20-70) 0.6855
Left ventricular function, n (%)
Severe dysfunction 11 (4.56) 13 (5.78)
Moderate dysfunction 10 (4.15) 7 (3.11)
Preserved function 18 (7.47) 17 (7.56)
Good function 202 (83.82) 188 (83.56)
Symptom, n (%)
Asymptomatic 28 (11.62) 20 (8.89)
Circulatory 128 (53.11) 117 (52)
Congestive heart failure 8 (3.32) 6 (2.67)
Fever 5 (2.07) 1 (0.44)
Embolic events 2 (0.83) 0 (0.00)
Cerebrovascular events 4 (1.66) 3 (1.33)
Hoarseness and cough 1 (0.41) 0 (0.00)
Abdominal pain 0 (0.00) 2 (0.89)
Other 0 (0.00) 8 (3.56)
Not recorded 65 (26.97) 68 (30.22)
Murmur, n (%)
No murmur 20 (8.30) 77 (34.22)
Systolic 146 (60.58) 51 (22.67)
Diastolic 31 (12.86) 32 (14.22)
Systolic and diastolic 17 (7.05) 13 (5.78)
Not recorded 27 (11.20) 52 (23.11)
Comorbidity, n (%)
Hypertension 74 (30.71) 94 (41.78)
Dyslipidemia 58 (24.07) 56 (24.89)
Coronary artery disease 55 (22.82) 65 (28.89)
Diabetes 26 (10.79) 35 (15.56)
Renal failure 20 (8.30) 23 (10.22)
Atrial fibrillation 20 (8.30) 30 (13.33)
Hypothyroidism 8 (3.32) 7 (3.11)
Ankylosing spondylitis 2 (0.83) 1 (0.44)
Cervical spondylitis 1 (0.41) 0 (0.00)
Associated congenital heart defects, n (%)
Coarctation of the aorta 10 (4.15) 1 (0.44)
Secundum atrial septal defect 1 (0.41) 0 (0.00)
Patent foramen ovale 0 (0.00) 6 (2.67)
Ventricular septal defect 1 (0.41) 0 (0.00)
Patent ductus arteriosus 2 (0.83) 0 (0.00)
Aortic stenosis 1 (0.41) 0 (0.00)
Lipid-lowering therapy, n (%) 86 (35.68) 70 (31.11)
Atorvastatin 11 (12.79) 7 (10)
Simvastatin 75 (87.21) 63 (90)
Postoperative stay (days) 6.34±3.45 (3-27, n=238) 8.42±7.25 (2-55, n=217) <0.0001
BAV=bicuspid aortic valve; TAV=tricuspid aortic valve.
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Aortic dilation was present in 97 (40.25%) of the 241 
patients that had BAVs. The aortic root was involved in 9 
(9.28%) patients, the ascending aorta was involved in 68 
(70.10%) patients, both the aortic root and the ascending 
aorta were involved in 14 (14.43%) patients, both the 
ascending aorta and aortic arch were involved in 5 (5.15%) 
patients, and the aortic root, ascending aorta, and aortic 
arch were involved in 1 patient (1.03%). The BAV patients 
that had evidence of aortic dilation were younger than their 
TAV counterparts and exhibited male gender predominance. 
The aortic annulus, aortic sinus, sinotubular junction, and 
ascending aorta were dilated in both BAV and TAV patients, 
and the dimensions of the aortic root and ascending aorta 
were much smaller in the BAV than in the TAV patients who 
were undergoing valvular surgery. In the absence of aortic 
dilation, significant differences were observed between the 
dimensions of the aortic root and the sinotubular junction in 
the BAV patients as compared to the TAV patients, with the 
former having larger dimensions (Table 4).
The length of the left main coronary artery could be 
measured in 86 patients with the BAVs and in 61 patients 
in the TAV group, all of whose coronary angiograms were 
available for viewing in the "Horizon Cardiology Web" of 
this hospital. A significant difference in the length of the 
left main coronary artery was noted between the patients 
with a BAV and those with a TAV (5.4669 ± 2.9332 mm 
vs. 7.4967 ± 6.7316 mm, p = 0.0141). The range of the left 
main coronary artery length was 1.1-15.2 mm in the former 
group and 0-30.8 mm in the latter group. The shortest left 
main coronary artery identified among the BAV patients was 
1.1 mm, while three patients with a TAV (who presented 
with type A aortic dissection, ascending aortic aneurysm, 
and ascending aortic aneurysm associated with aortic valve 
regurgitation, respectively) had absent left main coronary 
arteries and instead had left anterior descending coronary 
arteries and marginal arteries that bifurcated at the aortic 
sinus (Figure 3). 
In the BAV group, no differences were noted in the 
length of the left main coronary artery with regard to the 
cardiac circulation dominance type of the patients [right vs. 
left dominance 5.4381±3.3298 (range, 2.3-12.1) mm (n=36) 
vs. 6.1050 ±2.7765 (range, 1.9-15.2) mm (n=12), p=0.5357; 
right vs. codominance 5.4381±3.3298 (range, 2.3-12.1) mm 
(n=36) vs. 5.3009±2.7479 (range, 1.92-14.6) mm (n=34), 
p=0.4512; and left vs. codominance 6.1050 ±2.7765 (range, 
1.9-15.2) mm (n=12), vs. 5.3009±2.7479 (range, 1.92-14.6) 
mm (n=34), p=0.8519]. 
Table 2 - A comparison of the constitutional percentages between BAV and TAV patients of the entire study period.
Subgroup Pathology BAV TAV
Case Percentage of 
the group
Percentage of 
the pathology
Case Percentage of 
the group
Percentage of 
the pathology
1 aortic dilation 13 5.39 25.49 38 3.15 74.51
2 aortic dilation + aortic valve 
disorder
72 29.88 51.06 69 5.71 48.94
3 dissection of the aorta 4 1.66 6.15 61 5.05 93.85
4 coarctation of the aorta 10 4.15 90.91 1 0.08 9.09
5 Marfan’s syndrome 3 1.24 14.29 18 1.49 85.71
6 aortic valve disorder (aortic 
valve stenosis, regurgitation 
or combined)
126 52.28 17.65 588 48.68 82.35
7 infective endocarditis (1 had 
perivalvular abscesses)
9 3.73 10.71 75 6.21 89.29 
8 mitral regurgitation 4 1.66 1.10 358 29.64 98.90
BAV=bicuspid aortic valve; TAV=tricuspid aortic valve.
Table 3 - Functional parameters of the bicuspid aortic valve.
Valve function Case (%)
Aortic stenosis 122 (50.62%)
Severe 113 (92.62%)
Moderate-to-severe 4 (3.28%)
Moderate 3 (2.46%)
Mild 2 (1.64%)
Aortic regurgitation 62 (25.73%)
Severe 36 (58.06%)
Moderate-to-severe 6 (9.68%)
Moderate 8 (12.90%)
Mild-to-moderate 4 (6.45%)
Mild 7 (11.29%)
Minimal 1 (1.61%)]
Aortic stenosis + regurgitation 38 (15.77%) 
Normal 19 (7.88%)
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Homological parameters were much lower than normal 
limits. In the BAV group, there was no significant difference 
noted between the hemoglobin concentrations of patients 
without and with infective endocarditis [10.6947±1.1914 
(n=231) (range, 7.6-14.9) vs. 9.9744±1.3726 (n=9) (range, 
7.9-12.1), p= 0.0781].
There were no inter-group differences in the total 
cholesterol concentrations. However, intra-group differences 
were noted between patients receiving lipid-lowering therapy 
and those not receiving lipid-lowering therapy (Figure 4). The 
baseline dimensions of the aortic root, sinotubular junction, 
and ascending aorta were greater than the upper limit of 
normal in both groups, although those of the TAV patients 
tended to be larger than those of the BAV patients (Figure 
5). Multiple linear regression analysis did not show any 
strong correlations between the dimensions of the aorta and 
the length of the left main coronary artery or the total serum 
cholesterol concentration in the BAV group. However, aortic 
dimensions at the four levels that were measured were found 
to be significantly related to patient age (Y=0.823+0.748X1-
0.0253X2+0.383X3-0.00057X4; R = 0.749; R2 = 0.562; 
adjusted R2 = 0.552; F = 56.693; p<0.0001).
Figure 1 - Short axis views from intraoperative transesophageal echocar-
diography. (A) Type A bicuspid aortic valve with two commissures at 2 and 
8 o’clock and a raphe (arrow) at the 5 o’clock position. The anterior leaflet 
and the raphe are calcified. (B) Type B bicuspid aortic valve with two com-
missures at 5 and 11 o’clock and a raphe (arrow) at the 7-8 o’clock position. 
Both leaflets and the raphe are calcified. (C) Type C bicuspid aortic valve 
with two commissures at the 3-4 and 9 o’clock positions with no raphe. The 
leaflets were free of calcification.
Figure 2 - A short axis view of the aorta, showing the aortic valve. (A) Three 
commissures with equal-sized leaflets during diastole. (B) A characteristic 
doming configuration of a bicuspid aortic valve during systole. 
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DISCUSSION
Approximately 15-50% of the BAV patients retained 
their normal valvular function,11 while the others had 
dysfunctional valves at the early age of 61.3±12.8 years 
as compared to 67.5±12.9 years in the TAV patients.2 The 
BAV patients also exhibited a male gender predominance 
with regard to the occurrence of valvular dysfunction. 
Including the BAV patients who had infective endocarditis 
but normal functioning valves, 78.3% of the aortic 
valves of the BAV patients were stenotic, 15.6% were 
regurgitant, and 4% were both stenotic and regurgitant. 
In a previous report, Collins et al.2 found that among the 
BAV patients included in their study, calcification of the 
base, calcification of the commissure, and ossification were 
found in 39.1%, 43.3%, and 7% of the valves. 
Aortic dilation and aortic dissection accounted for 
50-70% and 7-13% of the BAV patients, respectively.7,12 
About 40% of the patients with Marfan’s syndrome had 
aortic dissections, and the BAVs were present in 5% of 
the Marfan’s patients.12 Except for the complications 
described in the literature, the presented BAV patient setting 
represented 1.66% of the patient population with mitral 
regurgitation, and one of them was associated with a large 
secundum atrial septal defect.13 The BAVs can be associated 
with other congenital cardiovascular lesions, including 
coarctation of the aorta, ventricular septal defects, patent 
ductus arteriosus, William's syndrome, Turner's syndrome, 
and Shone's syndrome.1 However, none of our BAV patients 
had any of these conditions.
Brandenburg et al.10 defined the morphological types of 
the BAVs based on the short axis view of the transthoracic 
echocardiogram. In type A BAVs, the posterior and anterior 
commissures and raphe are located at 4-5, 9-10, and 1-2 
o'clock, and the anterior leaflet is larger; in type B BAVs, the 
posterior and anterior commissures and raphe are located at 
Table 4 - Age, gender, and aortic dimensions of patients with and without aortic dilation.
Variable BAV TAV p-value
Subgroups 1 & 2 (with aortic dilation)
Age (year) 53.48±15.68 (n=85) 63.64±12.08 (n=107) <0.0001
Gender, M/F (n) 74/11=6.73:1 70/37=1.89:1
Aortic annulus (cm) 2.5153±0.5454 (n=189) 2.6057±0.0670 (n=63) 0.2530
Aortic root (cm) 4.0235±0.5519 (n=66) 4.3551±0.9435 (n=70) 0.0143
Sinotubular junction (cm) 3.7849±0.6381 (n=57) 3.9952±1.0312 (n=64) 0.1864
Ascending aorta (cm) 4.9968±0.6852 (n=80) 5.3638±1.1044 (n=97) 0.0104
Subgroups 6, 7, & 8 (without aortic dilation)
Age (year) 59.54±13.15 (n=139) 73.87±10.68 (n=38) <0.0001
Gender, M/F (n) 98/41=2.39:1 20/18 =1.11:1
Aortic annulus (cm) 2.3197±0.4431 (n=116) 2.1956±0.4970 (n=36) 0.1560
Aortic root (cm) 3.3746±0.5093 (n=115) 3.0828±0.4993 (n=36) 0.0030
Sinotubular junction (cm) 3.0170±0.5086 (n=113) 2.7510±0.7296 (n=31) 0.0211
Ascending aorta (cm) 3.6811±0.6100 (n=117) 3.5039±0.6849 (n=36) 0.1409
BAV=bicuspid aortic valve; TAV=tricuspid aortic valve.
Table 5 - Laboratory findings of patients undergoing aortic valve replacement.
Variable BAV TAV p-value
Prothrombin time (%) 53.55±27.26 (n=240) (range 9-120) 71.58±29.61 (n=220) (range 17-128) <0.0001
International normalized ratio 1.6699±0.6841 (n=240) (range 0.9-4.9) 1.3847±0.5652 (n=222) (range 0.89-3.55) <0.0001
Partial thromboplastin time (sec) 33.4125±6.3080 (n=240) (range 20-59) 33.8308±13.4102 (n=220) (range 22-150) 0.6647
Cholesterol (mg/dL) 130.41±30.50 (n=239) (range 63-246) 126.95±30.97 (n=223) (range 65-222) 0.2266
Hemoglobin (g/dL) 10.6677±1.2033 (n=240) (range 7.6-14.9) 10.8509±1.3307 (n=223) (range 7.9-16.5) 0.1205
Red blood cell (M/µL) 3.6748±0.4501 (n=239) (range 2.87-5.44) 3.7287±0.4715 (n=222) (range 2.7-5.17) 0.2097
Hematocrit (%) 31.8633±3.6299 (n=239) (range 22.5-45.1) 32.4768±3.8058 (n=222) (range 22.8-42.7) 0.0772
Platelet (K/µL) 219.977±91.540 (n=240) (range 57-625) 212.117±98.219 (n=223) (range 38-609) 0.3733
BAV=bicuspid aortic valve; TAV=tricuspid aortic valve.
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6, 1-2, and 9-10 o'clock, and the right leaflet is larger; and in 
type C BAVs, the commissures are at 3 and 9 o'clock, with 
no raphe, and the anterior and posterior leaflets are equal in 
size. In our study, as in previous studies, type A BAVs were 
most common, followed by type B and type C BAVs.14,15 
With echocardiography, it is possible to make a false positive 
diagnosis when the coaptation line of a TAV is faint, and a 
false negative diagnosis may be made if a prominent raphe 
is present in a BAV.16 However, only one patient in the 
present series had a false negative diagnosis based on their 
echocardiogram. In this patient, the aortic valve appeared to 
have three coaptations, but a specific doming configuration 
was present during systole. The diagnosis of a BAV was 
established intraoperatively.
A study on the aorta dimensions of patients with 
purely severely stenotic BAVs revealed that these patients 
developed a moderate dilation of the aorta at an early age, 
while controls that had TAVs did not.9 Yasuda et al.17 has 
proposed two causes concerning the association between the 
dilation of the ascending aorta and the BAVs: hemodynamic 
burden caused by aortic valvular disorder and congenital 
aortic fragility. They compared the echocardiographic 
characteristics of patients with the BAVs and with the TAVs 
Figure 3 - Images showing the absence of the left main coronary artery. (A) 
A 3-D reconstruction of a computerized tomography scan of the heart of a 
64-year-old male patient with an ascending aortic aneurysm and moderate-to-
severe aortic regurgitation with a tricuspid aortic valve. (B) A right anterior 
oblique view of the coronary angiogram of a 75-year-old male patient with 
a chronic type A aortic dissection and a tricuspid aortic valve. 
Figure 4 - Intra-group differences between patients receiving statin therapy 
and those not receiving statin therapy. (+) = receiving statin therapy; (-) = 
not receiving statin therapy; BAV = bicuspid aortic valve; TAV = tricuspid 
aortic valve.
Figure 5 - Dimensions of the aorta of patients receiving statin therapy as 
compared to those not receiving statin therapy. (+) = receiving statin therapy; 
(-) = not receiving statin therapy; AA=ascending aorta; BAV=bicuspid aortic 
valve; STJ=sinotubular junction; TAV=tricuspid aortic valve.
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and found that, in addition to the fact that aortic dilation 
occurred more rapidly in patients with the BAVs, a similar 
aortic dilation rate was observed in the BAV patients who 
underwent aortic valve replacement as compared to those 
who did not. They concluded that aortic valve replacement 
could prevent aortic dilation in patients with the TAVs but 
that in patients with the BAVs, aortic valve replacement 
could not prevent aortic dilatation.
Scholz et al.18 reported that 24% of the BAV patients 
in their study had a left dominant cardiac circulation. 
Additionally, they found that the incidence of this type of 
circulation was highest in patients with aortic coarctation 
regardless of whether these patients had a BAV or a TAV. 
Hutchins et al.19 found a higher incidence of left dominance, 
29%, in postmortem angiography among the patients 
with the BAVs in their study. They postulated that the left 
dominance that they observed may have resulted from 
decreased blood flow to the left side of the heart. In the BAV 
patients, the length of the left main coronary artery was 1.0 
± 0.3 cm (range, 0.6-1.3), 1.3 ± 0.2 cm (range, 0.6-1.8) and 
0.9 cm in patients with a left, right and codominant coronary 
artery circulation, respectively. No significant difference 
in the length of the left main coronary artery was found 
between the BAV and TAV patients or between patients with 
different types of coronary artery circulation dominance.20
Collins et al.2 reported a prevalence of infective 
endocarditis of 1.5% among patients with the BAVs in his 
study, while we observed a prevalence of 3.73%. Lamas and 
Eykyn11 reported that nearly one-third of the BAV patients 
with infective endocarditis in their study had valvular or 
myocardial abscesses, whereas perivalvular abscesses were 
present in 1/9 of the infective endocarditis patients with the 
BAVs in our series. Lamas and Eykyn11 found that among 50 
BAV patients with infective endocarditis, 86% had anemia 
with a mean hemoglobin level of 11.8±1.58 g/dL. Anemia 
can be a result of several disorders of the aorta and aortic 
valve. Diehm et al.21 reported that 30.7% of the abdominal 
aortic aneurysm patients had anemia at baseline in their 
study and that anemia was independently associated with 
aneurysmal size and reduced long-term survival following 
endovascular repair. Intravascular hemolysis and hemolytic 
anemia are sometimes seen in patients with aortic valve 
stenosis.22 It has therefore been suggested that severe aortic 
valve disorders may be associated with anemia, especially in 
non-survivors of such patients.23
An even younger age and a greater male gender 
predominance of the BAV patients were observed in this 
patient group than have been observed in previous studies. 
A previous study found that the BAVs were present in 1-15% 
of patients who suffered aortic dissections at <54 years of 
age.12 Those results were slightly different from our study, 
in which we observed an aortic dissection rate of 1.66% 
occurring at a median age of 68.5 (range, 28-77) years. 
In the present study, anemia was noted in both the BAV 
and TAV patients with and without infective endocarditis 
based on their hemoglobin levels, red blood cell counts, and 
hematocrits. In the BAV patients, the prothrombin time was 
shorter and the international normalized ratio was higher 
than the upper limit of normal, but the partial thromboplastin 
time was normal. 
An important result of this study that is contrary to 
reports in the literature24 is the disparity between the 
aortas of the BAV and TAV patients, in that the aortic 
dilation observed in the aortic root, sinotubular junction, 
and ascending aorta segments of the BAV patients 
undergoing surgery was less severe than that of the TAV 
patients undergoing surgery. A possible explanation for 
this phenomenon is that aortic dilation is age-related, a 
finding that has been previously described by Cecconi and 
associates, 5,6 because in our study, the BAV patients were 
much younger than the TAV patients. Recent retrospective 
trials 25,26 have demonstrated that it is possible to slow the 
progression of aortic stenosis with statin therapy, and statin 
therapy was therefore recommended to all the patients with 
aortic valve disorders in order to slow or prevent dilation 
of the aorta.27 Our results are in agreement with those of 
the previous study in that statin therapy has the potential 
to decrease the degree of aortic dilation that patients 
experience. In our study, statin therapy was associated with 
smaller dimensions of the aortic root, sinotubular segment, 
and ascending aorta in both groups. Interestingly, we found 
that statin therapy did not influence the dimension of the 
aortic annulus and was more effective among the TAV 
patients. 
In conclusion, the BAV patients in our study developed 
aortic wall and aortic valve disorders at a younger age than 
the TAV patients. There was also a male gender predominance 
among the BAV patients with aortic and valvular anomalies. 
The shorter left main coronary arteries that were observed in 
these patients may be responsible for the progressive course of 
these lesions. Aortic dilation was observed in the aortic roots, 
sinotubular junctions, and ascending aortas of both the BAV 
and TAV surgical patients. The degree of dilation was less 
marked in the BAV group and was also significantly related to 
age in that group. Statin therapy did not affect the dimensions 
of the aortic annulus in either group, but did decrease the 
dimensions of the aortic root, sinotubular junction, and 
ascending aorta in both groups, although it had a more marked 
effect in the TAV patients. To confirm the results of this study, 
a prospective study with a larger sample size and a matched 
control group should be performed.
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